CClinicalTrials.gg
Sign In
Not yet recruitingNCT06658418Updated Oct 26, 2024

Erector Spinae Plane Block with Dexmedetomidine and Bupivacain Versus Dexamethasone and Bupivacain for Postoperative Analgesia in Patients Undergoing Abdominal Surgeries

A Phase 1 interventional study of Erector Spinae Plane Block in Analgesia, Postoperative, sponsored by Loay Gamal. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by Loay Gamal · Phase 1, Interventional, and Prevention

Phase
Phase 1
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To compare the analgesic effect of dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries

02

Conditions studied

  • Analgesia, Postoperative

Browse trials for

03

In context

Agnosia

1,190 studies on the registry are indexed under Agnosia; 508 are open to participants now.

This study's planned enrollment of 90 is above the median of 78 across 1,024 interventional studies indexed under Agnosia.

Browse Agnosia studies →

Lead sponsor

This is the only study on the registry with Loay Gamal as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Age :18 years old and older. Patients undergoing open abdominal surgery.

Exclusion criteria

Exclusion Criteria:

  1. Patient refusal
  2. known sensitivity or contraindication to any of study drugs
  3. contraindications for local anesthesia
  4. Patients with local infection at site of puncture
  5. uncooperative patients
  6. history of psychological disorders or chronic pain and significant liver or renal disease.
05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    dexmedetomidine combined with bupivacaine

    use for Dexmedetomidine and bupivacain for erector spinae plane block

    Procedure: Erector Spinae Plane Block

  • Experimental
    dexamethasone combined with bupivacaine

    use of dexamethasone combined with bupivacaine for erector spinae plane block

    Procedure: Erector Spinae Plane Block

Interventions

  • ProcedureErector Spinae Plane Block

    dexmedetomidine combined with bupivacaine versus dexamethasone combined with bupivacaine for ultrasound-guided ESPB for postoperative pain control in patients scheduled for abdominal surgeries.

06

What researchers measure

Primary outcomes

  1. VAS score

    pain intensity using VAS score

    Time frame: at 30 minutes, 2, 4, 6, 8, 12, 16, 20, and 24 hours postoperative.

Secondary outcomes

  1. the time for requirement of first morphine dose

    the time for requirement of first morphine dose (hours)

    Time frame: at 30 minutes, 2, 4, 6, 8, 12, 16, 20, and 24 hours postoperative.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Gottschalk A, Durieux ME, Nemergut EC. Intraoperative methadone improves postoperative pain control in patients undergoing complex spine surgery. Anesth Analg. 2011 Jan;112(1):218-23. doi: 10.1213/ANE.0b013e3181d8a095. Epub 2010 Apr 24. PubMed 20418538 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06658418
Lead sponsor
Loay Gamal
Responsible party
Loay Gamal (LGamal, Assiut University) — Sponsor-investigator
First posted
Oct 26, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Oct 26, 2024

Study contacts

loay GAMAL loay Gamal, master
Contact
loaygamal94@gmail.com
+201017675686

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Agnosia→

Start the discussion